System-level barriers linked to delays and poorer survival in 1,100 women with primary breast cancer
Distance and cost drive higher breast cancer death rates
This retrospective cohort study examined 1,100 women diagnosed with primary breast cancer using hospital records and administrative database…
New data shows travel distance and cost delay care and raise death rates for rural women facing breast cancer.
Preoperative HALP, SII, and LMR scores predict disease-free survival in stage III colon cancer patients
Blood markers linked to recurrence risk in colon cancer patients
This retrospective cohort study evaluated preoperative HALP, SII, and LMR scores in 210 patients with stage III colon cancer and 220 patient…
A new analysis suggests certain blood markers might help estimate recurrence risk for colon cancer patients after surgery.
TP53 and PTEN mutations detected in 68% and 47% of ovarian and endometrial cancer samples respectively in a retrospective cohort
Genetic markers found in swabs may help spot ovarian and endometrial cancers
This retrospective cohort study evaluated 238 women across three tertiary hospitals between 2018 and 2023.
A new look at genetic markers in swabs shows they appear in most ovarian and endometrial cancer cases, offering a potential new way to find …
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC
Salvage therapy works better than upfront treatment for some esophageal cancer patients
This retrospective analysis of 91 patients from 3 medical centers compared salvage versus upfront definitive chemoradiotherapy (DCRT) for lo…
New data shows treating esophageal cancer after a failed first attempt may lead to better outcomes than starting with the strongest drugs im…
Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
Small kidney tumors may not need surgery right away
This prospective multi-institutional study evaluated active surveillance in patients aged over 50 years with asymptomatic, unilateral small …
Many small kidney tumors stay harmless for years, meaning patients might avoid surgery and its risks without putting their health in danger.
FDA Approves Perjeta (pertuzumab) for HER2-Positive Breast Cancer
FDA approves new drug Perjeta for HER2-positive breast cancer
The FDA approved Perjeta (pertuzumab) for use in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer an…
The FDA approved Perjeta (pertuzumab) for HER2-positive breast cancer.
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis
Fatty liver makes autoimmune hepatitis and PBC worse, but not PSC
This systematic review and meta-analysis of 19,898 patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing c…
A large review found fatty liver is common in autoimmune liver diseases and makes outcomes worse for some patients, but not others.
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield
Doctors find a better way to sample swollen lymph nodes safely
This systematic review and network meta-analysis evaluated diagnostic yield across EBUS techniques in 2357 patients with mediastinal and/or …
A new freezing biopsy technique finds the cause of swollen chest nodes more often than standard needles while staying safe for patients.
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Narrative review on precision prevention for women with inherited gynecologic cancer susceptibility
New Plan Cuts Cancer Risk for High-Risk Women
This narrative review addresses ovarian, endometrial, and fallopian tube cancer in women with inherited gynecologic cancer susceptibility.
Women with strong family histories of ovarian or uterine cancer can now take smarter, personalized steps to reduce their risk — and it’s cha…
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…